149 related articles for article (PubMed ID: 28699528)
1. Targeting CD147 is a Novel Strategy for Antitumor Therapy.
Lian C; Guo Y; Zhang J; Chen X; Peng C
Curr Pharm Des; 2017 Nov; 23(29):4410-4421. PubMed ID: 28699528
[TBL] [Abstract][Full Text] [Related]
2. Repressing CD147 is a novel therapeutic strategy for malignant melanoma.
Hu X; Su J; Zhou Y; Xie X; Peng C; Yuan Z; Chen X
Oncotarget; 2017 Apr; 8(15):25806-25813. PubMed ID: 28445958
[TBL] [Abstract][Full Text] [Related]
3. CD147/EMMPRIN: an effective therapeutic target for hepatocellular carcinoma.
Tang X; Guo N; Xu L; Gou X; Mi M
J Drug Target; 2013 Apr; 21(3):224-231. PubMed ID: 22931464
[TBL] [Abstract][Full Text] [Related]
4. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression.
Nabeshima K; Iwasaki H; Koga K; Hojo H; Suzumiya J; Kikuchi M
Pathol Int; 2006 Jul; 56(7):359-67. PubMed ID: 16792544
[TBL] [Abstract][Full Text] [Related]
5. CD147/basigin promotes progression of malignant melanoma and other cancers.
Kanekura T; Chen X
J Dermatol Sci; 2010 Mar; 57(3):149-54. PubMed ID: 20060267
[TBL] [Abstract][Full Text] [Related]
6. Structural insights on druggable hotspots in CD147: A bull's eye view.
Kumar D; Vetrivel U; Parameswaran S; Subramanian KK
Life Sci; 2019 May; 224():76-87. PubMed ID: 30904494
[TBL] [Abstract][Full Text] [Related]
7. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions.
Sun J; Hemler ME
Cancer Res; 2001 Mar; 61(5):2276-81. PubMed ID: 11280798
[TBL] [Abstract][Full Text] [Related]
8. Expression and clinical significance of CD147 in genitourinary carcinomas.
Han ZD; He HC; Bi XC; Qin WJ; Dai QS; Zou J; Ye YK; Liang YX; Zeng GH; Zhu G; Chen ZN; Zhong WD
J Surg Res; 2010 May; 160(2):260-7. PubMed ID: 19286191
[TBL] [Abstract][Full Text] [Related]
9. The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature.
Xiong L; Edwards CK; Zhou L
Int J Mol Sci; 2014 Sep; 15(10):17411-41. PubMed ID: 25268615
[TBL] [Abstract][Full Text] [Related]
10. Biological Characteristics of Cluster of Differentiation 147 and Its Relationship with Tumour.
Gao C; Lu CH; Chen J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):589-593. PubMed ID: 27825419
[TBL] [Abstract][Full Text] [Related]
11. Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma.
Lu Q; Lv G; Kim A; Ha JM; Kim S
Oncol Lett; 2013 Jan; 5(1):201-207. PubMed ID: 23255920
[TBL] [Abstract][Full Text] [Related]
12. A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells.
Fu ZG; Wang L; Cui HY; Peng JL; Wang SJ; Geng JJ; Liu JD; Feng F; Song F; Li L; Zhu P; Jiang JL; Chen ZN
Oncotarget; 2016 Feb; 7(8):9429-47. PubMed ID: 26882566
[TBL] [Abstract][Full Text] [Related]
13. A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis.
Su J; Chen X; Kanekura T
Cancer Lett; 2009 Jan; 273(1):140-7. PubMed ID: 18778892
[TBL] [Abstract][Full Text] [Related]
14. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts.
Kanekura T; Chen X; Kanzaki T
Int J Cancer; 2002 Jun; 99(4):520-8. PubMed ID: 11992541
[TBL] [Abstract][Full Text] [Related]
15. CD147 and MMPs as key factors in physiological and pathological processes.
Asgari R; Vaisi-Raygani A; Aleagha MSE; Mohammadi P; Bakhtiari M; Arghiani N
Biomed Pharmacother; 2023 Jan; 157():113983. PubMed ID: 36370522
[TBL] [Abstract][Full Text] [Related]
16. Soluble extracellular matrix metalloproteinase inducer (EMMPRIN, EMN) regulates cancer-related cellular functions by homotypic interactions with surface CD147.
Knutti N; Kuepper M; Friedrich K
FEBS J; 2015 Nov; 282(21):4187-200. PubMed ID: 26277583
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2 cells.
Zhu C; Pan Y; He B; Wang B; Xu Y; Qu L; Bao Q; Tian F; Wang S
Oncol Rep; 2011 Feb; 25(2):425-32. PubMed ID: 21165561
[TBL] [Abstract][Full Text] [Related]
18. How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity.
Grass GD; Toole BP
Biosci Rep; 2015 Nov; 36(1):e00283. PubMed ID: 26604323
[TBL] [Abstract][Full Text] [Related]
19. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
Zucker S; Cao J; Chen WT
Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
[TBL] [Abstract][Full Text] [Related]
20. Cleaved CD147 shed from the surface of malignant melanoma cells activates MMP2 produced by fibroblasts.
Hatanaka M; Higashi Y; Fukushige T; Baba N; Kawai K; Hashiguchi T; Su J; Zeng W; Chen X; Kanekura T
Anticancer Res; 2014 Dec; 34(12):7091-6. PubMed ID: 25503136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
